stock-detail (SGEN)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

Biosimilar Shows Comparable Efficacy, Safety to Trastuzumab in Advanced Breast Cancer

6/3/2016 02:01 pm

(ASCO Annual Meeting) June 3, 2016 - A biosimilar trastuzumab antibody (MYL-­1401O) is comparable in efficacy and safety to the FDA-approved targeted breast cancer drug trastuzumab (Herceptin) in women with HER2-­positive advanced breast cancer, according to a randomized phase III study.

FDA to Review Bristol-Myers’s Opdivo for Hodgkin Lymphoma

4/14/2016 12:03 pm

(Morningstar/Dow Jones Newswires) Apr 14, 2016 - The U.S. Food and Drug Administration has accepted Bristol-Myers Squibb Co.’s supplemental biologics license application to expand the use of its cancer drug Opdivo to patients who are facing difficult-to-treat variations of Hodgkin lymphoma, the pharmaceutical company said Thursday.

Specific Gene In The Tumor Determines The Effectiveness Of Cancer Treatment

4/14/2016 11:01 am

(MedUni Vienna [Austria]) Apr 14, 2016 - Mutations in the TP53 gene can have harmful consequences.

How Medicare Drug Plans Hope To Follow Private Sector Lead

3/18/2016 10:02 am

(Kaiser Health News) Mar 18, 2016 - Aetna and Cigna inked deals in early February with drugmaker Novartis that offer the insurers rebates tied to how well a pricey new heart failure drug works to cut hospitalizations and deaths.

Provectus Biopharmaceuticals Initiating Phase 1 Study of PV-10 in Neuroendocrine Tumors Metastatic to Liver

2/29/2016 12:00 pm

(StreetInsider) Feb 29, 2016 - Provectus Biopharmaceuticals, Inc. today announced that it is initiating a protocol titled, “A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products.”

FDA Gives Ocrelizumab Breakthrough Designation For PPMS: Roche

2/17/2016 12:03 pm

(Reuters) Feb 17, 2016 - The U.S. Food and Drug Administration has granted breakthrough therapy designation for ocrelizumab (OCREVUS) for treating people with primary progressive multiple sclerosis (PPMS), Swiss drugmaker Roche said on Wednesday.

Smoking Lowers Breast Cancer Survival, Study Finds

1/27/2016 07:02 am

(Philadelphia Inquirer/HealthDay News) Jan 26, 2016 - Women diagnosed with breast cancer who continue to smoke cigarettes are less likely to survive than those who never smoked or those who quit, new research finds.

Immune System Takes Long Time To Recover After Breast Cancer Chemo

1/26/2016 11:02 am

(Medical News Today) Jan 26, 2016 - New research that looks at the long-term effects of chemotherapy on breast cancer survivors finds it weakens parts of the immune system for at least 9 months after treatment. This could leave patients with insufficient resilience to common infections, such as pneumonia and tetanus, even if they were immunized previously, say the researchers.

Eisai Files Kidney Cancer Drug In Europe

1/12/2016 12:00 pm

(PharmaTimes [UK]) Jan 12, 2016 - Eisai has submitted an application to market its oncology drug lenvatinib for the treatment of patients with renal cell carcinoma.

Gritstone Oncology Enters Into Exclusive Licensing Agreement and Collaboration with Memorial Sloan Kettering Cancer Center

1/12/2016 11:05 am

(WDRB 41 Louisville News) Jan 12, 2016 - Agreement will support discovery and development of personalized cancer immunotherapies.

Enumeral and MD Anderson Enter Into Collaborative Research and Development Agreement

1/12/2016 11:05 am

(Yahoo! Finance) Jan 11, 2016 - Strategic collaboration aims to discover and develop potentially novel antibodies against specified targets for immunotherapy.

Forma Therapeutics Achieves An Additional Major Objective In Collaboration With Celgene Corporation To Advance Innovative Protein Homeostasis Drugs

1/12/2016 11:05 am

(FORMA) Jan 12, 2016 - FORMA Therapeutics announced today that it has successfully met a third objective under its strategic collaboration agreement with Celgene Corporation, triggering an undisclosed payment from Celgene.

Independence Blue Cross to Cover Whole Genome Sequencing

1/12/2016 11:05 am

(Philadelphia Business Journal) Updated Jan 12, 2016 - Independence Blue Cross entered into an agreement with NantHealth to cover next-generation whole genome sequencing for a variety of cancers.

Human Longevity, Inc. to Offer Oncology Products Including Comprehensive Whole Germline, Tumor Genome and Whole Cancer Exome Products

1/12/2016 11:05 am

(HLI) Jan 12, 2016 - Human Longevity, Inc., the genomics-based, technology-driven company, announced today its oncology genomics program, including the development of comprehensive whole germline and tumor genome analysis, as well as tumor and germline exome analysis products.

For Cancer Survivors, Expenses Keep Mounting

1/12/2016 11:05 am

(U.S. News & World Report/HealthDay News) Jan 12, 2016 - A cancer diagnosis is costly, and new research suggests that it remains costly even after the disease has been treated.

Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement

1/12/2016 11:04 am

(ACP/Annals of Internal Medicine) Jan 12, 2016 - Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for breast cancer.

New Analyses Confirms Biennial Mammography Starting At Age 50 Optimal For Average Women

1/12/2016 11:04 am

(GUMC) Jan 11, 2016 - Unanimous finding of six research teams on breast cancer screening provided to USPSTF.

Susan G. Komen®: Women and Health Care Providers Should Have the Final Say on Mammogram Schedules

1/12/2016 11:04 am

(Yahoo! Finance) Jan 11, 2016 - Komen renews concern over Task Force proposal to raise routine mammography age.

Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program

1/12/2016 11:04 am

(Merck) Jan 11, 2016 - Acquisition grows Merck’s oncology pre-clinical pipeline with novel IDO1 and TDO inhibitors.

BioLineRx Announces Collaboration with MSD to Investigate the Combination of KEYTRUDA (pembrolizumab) and BL-8040 in Pancreatic Cancer

1/12/2016 11:04 am

(BioLineRx ) Jan 12, 2016 - BioLineRx Ltd. today announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study investigating BioLineRx's BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer.

Federal Panel Finalizes Mammogram Advice That Stirred Controversy

1/12/2016 06:05 am

(NPR/Shots blog) Jan 11, 2016 - After the public had a chance to comment, the influential U.S. Preventive Services Task Force has finalized their latest breast cancer screening recommendations, reiterating that women ages 50-74 ought to receive a screening mammogram every two years.

New Breast Cancer Screening Guidelines At Odds With Congress

1/12/2016 06:04 am

(Washington Post) Jan 11, 2016 - Congress has sided with proponents of earlier screening.

Novartis Signs $170 Million Immuno-Oncology Pact With Surface

1/11/2016 12:05 pm

(Reuters) Jan 11, 2016 - Novartis AG has struck a $170 million alliance with U.S.-based Surface Oncology as it seeks to boost its portfolio of medicines that help the body's immune system fight cancer.

Cyrus Ghajar Receives $4.1M Grant to Study Ways to Prevent Metastatic Breast Cancer

6/30/2015 12:01 pm

(Fred Hutch News) June 29, 2015 – Cyrus Ghajar, Ph.D., a metastatic breast cancer researcher at Fred Hutchinson Cancer Research Center, has received a $4.1 million Department of Defense Breast Cancer Research Program (BCRP) “Era of Hope” Scholar Award.

GenomeDx Announces Launch of Decipher GRID™ and Partnership with Sidney Kimmel Cancer Center to Accelerate Innovation in Urologic Cancer Patient Care

5/12/2015 12:00 pm

(GenomeDx) May 12, 2015 - GenomeDx Biosciences today announced the launch of the Decipher® Genomics Resource Information Database (Decipher GRID™), a clinical genomics data sharing program that unites patient registries from leading cancer centers with GenomeDx's full genome profiling platform.